Previous 10 | Next 10 |
TherapeuticsMD (NASDAQ: TXMD ) has signed a binding commitment letter for a fully-negotiated $300M non-dilutive secured term loan financing facility with TPG Sixth Street Partners (“TSSP”). More news on: TherapeuticsMD, Inc., Healthcare stocks news, Stocks on the move, ...
Leading Healthcare Investor Will Provide TherapeuticsMD with Strategic Growth Capital Additional Non-Dilutive Funding Will Support the Launches of BIJUVA TM and ANNOVERA TM TherapeuticsMD, Inc. (NASDAQ:TXMD), an innovative, leading women’s healthcare company, today announced...
-BIJUVA is the only FDA-approved Therapy Combining Bio-identical Estradiol and Progesterone for Moderate to Severe Vasomotor Symptoms due to Menopause in a Single Capsule- -Company to Hold Investor Day in New York on Monday, June 10, 2019- TherapeuticsMD, Inc. (NASDAQ: TXMD), an inno...
Four Posters Will Present BIJUVA Phase 3 REPLENISH Data About Improvements in Hot Flushes, Night Sweats, Sweating, Quality of Sleep, and Incidence of Vaginal Bleeding in Postmenopausal Women One Oral Presentation and One Poster Will Present ANNOVERA Phase 3 Data About Antiovulatory Eff...
The following slide deck was published by TherapeuticsMD, Inc. in conjunction with this Read more ...
The following slide deck was published by TherapeuticsMD, Inc. in conjunction with this Read more ...
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced the schedule of oral presentations on clinical data for BIJUVA TM (estradiol and progesterone capsules, 1 mg/100 mg) and ANNOVERA TM (segesterone acetate/ethinyl estradiol vaginal...
TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, today announced that the company will participate in two upcoming healthcare conferences. Chief Executive Officer Robert G. Finizio will provide an overview of the company at the conferences. D...
TherapeuticsMD (TXMD) Q4 2018 Earnings Conference Call February 21, 2019 4:30 PM ET Company Participants Nichol Ochsner - Vice President of Investor Relations Robert Finizio - Chief Executive Officer Daniel Cartwright - Chief Financial Officer Brian Bernick - Co-Founder & D...
The following slide deck was published by TherapeuticsMD in conjunction with their 2018 Q4 earnings Read more ...
News, Short Squeeze, Breakout and More Instantly...
TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Results Net Income (...
• Evaluation of strategic alternatives continues TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2023...